Access and Optimism: IRA Reforms and the Road Ahead in PCa Care

7 Views
Published
At the American Urological Association 2025 Annual Meeting, an expert panel convened to discuss the latest research and clinical advancements in metastatic hormone-sensitive prostate cancer (mHSPC) diagnostics and treatment. Moderated by Murilo De Almeida Luz, MD, Icahn School of Medicine at Mount Sinai, the roundtable consisted of Gordon Brown, DO, Summit Health; Daniel Oberlin, MD, Golden Gate Urology; and Gregory C. McMahon, DO, MidLantic Urology.

In the final segment of the discussion, the panel concludes with a discussion on how recent Medicare Part D reforms have improved access to advanced prostate cancer treatments by capping out-of-pocket costs, followed by each expert offering optimistic final reflections on the future of care.
Category
Oncology
Be the first to comment